Development and application of two novel monoclonal antibodies against overexpressed CD26 and integrin α3 in human pancreatic cancer

Monoclonal antibody (mAb) technology is an excellent tool for the discovery of overexpressed cell surface tumour antigens and the development of targeting agents. Here, we report the development of two novel mAbs against CFPAC-1 human pancreatic cancer cells. Using ELISA, flow cytometry, immunopreci...

Descripción completa

Detalles Bibliográficos
Autores principales: Arias-Pinilla, Gustavo A., Dalgleish, Angus G., Mudan, Satvinder, Bagwan, Izhar, Walker, Anthony J., Modjtahedi, Helmout
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6969035/
https://www.ncbi.nlm.nih.gov/pubmed/31953437
http://dx.doi.org/10.1038/s41598-019-57287-w

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6969035/
https://www.ncbi.nlm.nih.gov/pubmed/31953437
http://dx.doi.org/10.1038/s41598-019-57287-w

Ejemplares similares